Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Alliance Pharmaceuticals Ltd, Avonbridge House, 2 Bath Road, Chippenham, Wiltshire, SN15 2BB, UK
Isocarboxazid is a monoamine oxidase inhibitor, effective in small doses. Its antidepressant action is thought to be related to its effect on physiological amines such as serotonin and noradrenaline, and this effect is cumulative and persistent.
Isocarboxazid is readily absorbed after oral administration. Most of the drug-related material is excreted as metabolites in the urine.
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
